U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C4H4FN3O
Molecular Weight 129.0925
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FLUCYTOSINE

SMILES

NC1=NC(=O)NC=C1F

InChI

InChIKey=XRECTZIEBJDKEO-UHFFFAOYSA-N
InChI=1S/C4H4FN3O/c5-2-1-7-4(9)8-3(2)6/h1H,(H3,6,7,8,9)

HIDE SMILES / InChI

Molecular Formula C4H4FN3O
Molecular Weight 129.0925
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created using several sources including: http://www.uptodate.com/contents/pharmacology-of-flucytosine-5-fc; http://www.ncbi.nlm.nih.gov/pubmed/6338821; http://www.ncbi.nlm.nih.gov/pubmed/10933638

Flucytosine (5-flucytosine, Ancobon) is an antifungal agent used for treatment of serious fungal infections caused by Candida or Cryptococcus. A fluorinated cytosine analog it was originally developed as an anti-tumor agent, but was found to be non-effective against tumors. Monotherapy with 5-FC is limited because of the frequent development of pathogens resistance. It is often used in in combination with amphotericin B. The severe side effects of 5-flucytosine include hepatotoxicity and bone-marrow depression. 5-fluorocytosine is a prodrug to the cytotoxic compound 5-fluorouracil. Although the exact mode of action is unknown, it has been proposed that flucytosine acts directly on fungal organisms by competitive inhibition of purine and pyrimidine uptake and indirectly by intracellular metabolism to 5-fluorouracil. Flucytosine is taken up by fungal organisms via the enzyme cytosine permease. Inside the fungal cell, flucytosine is rapidly converted to fluorouracil by the enzyme cytosine deaminase. Fluorouracil exerts its antifungal activity through the subsequent conversion into several active metabolites, which inhibit protein synthesis by being falsely incorporated into fungal RNA or interfere with the biosynthesis of fungal DNA through the inhibition of the enzyme thymidylate synthetase.

Originator

Curator's Comment: Originally synthesized in 1957 by Duschinsky R. and Pleven E. from Hoffmann-LaRoche as an anti-cancer agent # Hoffmann-LaRoche, Inc

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
ANCOBON

Approved Use

INDICATIONS & USAGE Flucytosine Capsules is indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus. Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine Capsules should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine Capsules (see MICROBIOLOGY).

Launch Date

1971
Curative
ANCOBON

Approved Use

INDICATIONS & USAGE Flucytosine Capsules is indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus. Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine Capsules should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine Capsules (see MICROBIOLOGY).

Launch Date

1971
Curative
ANCOBON

Approved Use

INDICATIONS & USAGE Flucytosine Capsules is indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus. Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine Capsules should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine Capsules (see MICROBIOLOGY).

Launch Date

1971
Curative
ANCOBON

Approved Use

INDICATIONS & USAGE Flucytosine Capsules is indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus. Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine Capsules should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine Capsules (see MICROBIOLOGY).

Launch Date

1971
Curative
ANCOBON

Approved Use

INDICATIONS & USAGE Flucytosine Capsules is indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus. Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine Capsules should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine Capsules (see MICROBIOLOGY).

Launch Date

1971
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
57.3 mg/L
1500 mg single, oral
dose: 1500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLUCYTOSINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
506 mg × h/L
1500 mg single, oral
dose: 1500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLUCYTOSINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8.11 h
1500 mg single, oral
dose: 1500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FLUCYTOSINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
96.6%
FLUCYTOSINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
150 mg/kg 1 times / day multiple, oral (total daily dose)
Recommended
Dose: 150 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/kg, 1 times / day
Co-administed with::
fluconazole, p.o(400 mg/d)
Sources: Page: p.743
unhealthy, 34
n = 32
Health Status: unhealthy
Condition: Cryptococcal meningitis
Age Group: 34
Sex: M
Population Size: 32
Sources: Page: p.743
Disc. AE: Vomiting, Nausea...
AEs leading to
discontinuation/dose reduction:
Vomiting (9.4%)
Nausea (9.4%)
Diarrhea (6.25%)
Granulocytopenia (6.25%)
Thrombocytopenia (3.1%)
Rash (3.1%)
Sources: Page: p.743
150 mg/kg 4 times / day multiple, oral (total daily dose|max)
Recommended
Dose: 150 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 150 mg/kg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections caused by susceptible strains of Candida and/or Cryptococcus
Sources:
AEs

AEs

AESignificanceDosePopulation
Rash 3.1%
Disc. AE
150 mg/kg 1 times / day multiple, oral (total daily dose)
Recommended
Dose: 150 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/kg, 1 times / day
Co-administed with::
fluconazole, p.o(400 mg/d)
Sources: Page: p.743
unhealthy, 34
n = 32
Health Status: unhealthy
Condition: Cryptococcal meningitis
Age Group: 34
Sex: M
Population Size: 32
Sources: Page: p.743
Thrombocytopenia 3.1%
Disc. AE
150 mg/kg 1 times / day multiple, oral (total daily dose)
Recommended
Dose: 150 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/kg, 1 times / day
Co-administed with::
fluconazole, p.o(400 mg/d)
Sources: Page: p.743
unhealthy, 34
n = 32
Health Status: unhealthy
Condition: Cryptococcal meningitis
Age Group: 34
Sex: M
Population Size: 32
Sources: Page: p.743
Diarrhea 6.25%
Disc. AE
150 mg/kg 1 times / day multiple, oral (total daily dose)
Recommended
Dose: 150 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/kg, 1 times / day
Co-administed with::
fluconazole, p.o(400 mg/d)
Sources: Page: p.743
unhealthy, 34
n = 32
Health Status: unhealthy
Condition: Cryptococcal meningitis
Age Group: 34
Sex: M
Population Size: 32
Sources: Page: p.743
Granulocytopenia 6.25%
Disc. AE
150 mg/kg 1 times / day multiple, oral (total daily dose)
Recommended
Dose: 150 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/kg, 1 times / day
Co-administed with::
fluconazole, p.o(400 mg/d)
Sources: Page: p.743
unhealthy, 34
n = 32
Health Status: unhealthy
Condition: Cryptococcal meningitis
Age Group: 34
Sex: M
Population Size: 32
Sources: Page: p.743
Nausea 9.4%
Disc. AE
150 mg/kg 1 times / day multiple, oral (total daily dose)
Recommended
Dose: 150 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/kg, 1 times / day
Co-administed with::
fluconazole, p.o(400 mg/d)
Sources: Page: p.743
unhealthy, 34
n = 32
Health Status: unhealthy
Condition: Cryptococcal meningitis
Age Group: 34
Sex: M
Population Size: 32
Sources: Page: p.743
Vomiting 9.4%
Disc. AE
150 mg/kg 1 times / day multiple, oral (total daily dose)
Recommended
Dose: 150 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/kg, 1 times / day
Co-administed with::
fluconazole, p.o(400 mg/d)
Sources: Page: p.743
unhealthy, 34
n = 32
Health Status: unhealthy
Condition: Cryptococcal meningitis
Age Group: 34
Sex: M
Population Size: 32
Sources: Page: p.743
PubMed

PubMed

TitleDatePubMed
Comparison of the Etest and microdilution method for antifungal susceptibility testing of Cryptococcus neoformans to four antifungal agents.
2000 Dec
Synthesis and antifungal activities of 5/6-arylamino-4,7-dioxobenzothiazoles.
2000 Jul 17
Activity of voriconazole against Candida albicans and Candida krusei isolated since 1984.
2000 Nov
In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens.
2000 Oct
Update on HER-2 as a target for cancer therapy: the ERBB2 promoter and its exploitation for cancer treatment.
2001
The therapeutic monitoring of antimicrobial agents.
2001
Impact of endpoint definition on the outcome of antifungal susceptibility tests with Candida species: 24- versus 48-h incubation and 50 versus 80% reduction in growth.
2001
Imaging biochemistry: applications to breast cancer.
2001
Flucytosine primary resistance in Candida species and Cryptococcus neoformans.
2001 Apr
Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum.
2001 Apr
[Visceral mycotic infections. In clinical practice].
2001 Apr 15
Hepatic intra-arterial delivery of a retroviral vector expressing the cytosine deaminase gene, controlled by the CEA promoter and intraperitoneal treatment with 5-fluorocytosine suppresses growth of colorectal liver metastases.
2001 Aug
Carcinoembryonic antigen-specific suicide gene therapy of cytosine deaminase/5-fluorocytosine enhanced by the cre/loxP system in the orthotopic gastric carcinoma model.
2001 Aug 15
Candida lusitaniae catheter-related sepsis.
2001 Dec
Candida glabrata infection after total hip arthroplasty.
2001 Jan
Discontinuation of secondary prophylaxis against cryptococcosis in patients with AIDS receiving highly active antiretroviral therapy.
2001 Jul 27
In vitro susceptibility pattern of Sporothrix schenckii strains isolated from three centers in India.
2001 Jun
[In vitro antifungal susceptibility of dematiaceous filamentous fungi using the E-test].
2001 Jun
Combined topical flucytosine and amphotericin B for refractory vaginal Candida glabrata infections.
2001 Jun
Azasordarins: susceptibility of fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida spp. to GW 471558.
2001 Jun
The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines.
2001 Jun 1
Interactions of posaconazole and flucytosine against Cryptococcus neoformans.
2001 May
Evaluation of amphotericin B and flucytosine in combination against Candida albicans and Cryptococcus neoformans using time-kill methodology.
2001 Nov
Effect of the growth medium on the in vitro antifungal activity of micafungin (FK-463) against clinical isolates of Candida dubliniensis.
2001 Nov
In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase.
2001 Oct
Post-antifungal effect of polyene, azole and DNA-analogue agents against oral Candida albicans and Candida tropicalis isolates in HIV disease.
2001 Sep
Negative selection of Plasmodium falciparum reveals targeted gene deletion by double crossover recombination.
2002 Jan
Patents

Sample Use Guides

The usual dosage is 50 to 150 mg/kg/day administered in divided doses at 6- hour intervals.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: Standardized procedure of flucytosine MIC determination based on a dilution method with standardized inoculum and flucytosine powder concentrations.
MIC ≤4 ug/ml for susceptible pathogen
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:02:47 GMT 2023
Edited
by admin
on Fri Dec 15 15:02:47 GMT 2023
Record UNII
D83282DT06
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FLUCYTOSINE
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
5-FLUOROCYTOSINE [WHO-IP]
Common Name English
RO-29915
Code English
RO 2-9915
Code English
ANCOBON
Brand Name English
FLUCYTOSINE [WHO-IP]
Common Name English
5-Fluorocytosine
WHO-IP  
Systematic Name English
FLUCYTOSINE [USP IMPURITY]
Common Name English
FLUOROCYTOSINE
Systematic Name English
FLUCYTOSINE [MI]
Common Name English
NSC-103805
Code English
RO-2-9915
Code English
FLUCYTOSINE [HSDB]
Common Name English
FLUCYTOSINE [USAN]
Common Name English
Flucytosine [WHO-DD]
Common Name English
FLUCYTOSINE [ORANGE BOOK]
Common Name English
CYTOSINE, 5-FLUORO-
Systematic Name English
4-AMINO-5-FLUOROPYRIMIDIN-2(1H)-ONE [WHO-IP]
Systematic Name English
FLUCYTOSINE [EP MONOGRAPH]
Common Name English
FLUCYTOSINE [MART.]
Common Name English
FLUCYTOSINE [USP-RS]
Common Name English
FLUCYTOSINE [USP MONOGRAPH]
Common Name English
FLUCYTOSINE [JAN]
Common Name English
EMTRICITABINE IMPURITY E [WHO-IP]
Common Name English
FLUCYTOSINUM [WHO-IP LATIN]
Common Name English
flucytosine [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1557
Created by admin on Fri Dec 15 15:02:48 GMT 2023 , Edited by admin on Fri Dec 15 15:02:48 GMT 2023
WHO-ATC D01AE21
Created by admin on Fri Dec 15 15:02:48 GMT 2023 , Edited by admin on Fri Dec 15 15:02:48 GMT 2023
WHO-ATC J02AX01
Created by admin on Fri Dec 15 15:02:48 GMT 2023 , Edited by admin on Fri Dec 15 15:02:48 GMT 2023
EU-Orphan Drug EU/3/18/1978
Created by admin on Fri Dec 15 15:02:48 GMT 2023 , Edited by admin on Fri Dec 15 15:02:48 GMT 2023
WHO-VATC QJ02AX01
Created by admin on Fri Dec 15 15:02:48 GMT 2023 , Edited by admin on Fri Dec 15 15:02:48 GMT 2023
NDF-RT N0000175467
Created by admin on Fri Dec 15 15:02:48 GMT 2023 , Edited by admin on Fri Dec 15 15:02:48 GMT 2023
NDF-RT N0000175459
Created by admin on Fri Dec 15 15:02:48 GMT 2023 , Edited by admin on Fri Dec 15 15:02:48 GMT 2023
WHO-VATC QD01AE21
Created by admin on Fri Dec 15 15:02:48 GMT 2023 , Edited by admin on Fri Dec 15 15:02:48 GMT 2023
NDF-RT N0000175459
Created by admin on Fri Dec 15 15:02:48 GMT 2023 , Edited by admin on Fri Dec 15 15:02:48 GMT 2023
LIVERTOX NBK548624
Created by admin on Fri Dec 15 15:02:48 GMT 2023 , Edited by admin on Fri Dec 15 15:02:48 GMT 2023
NDF-RT N0000175459
Created by admin on Fri Dec 15 15:02:48 GMT 2023 , Edited by admin on Fri Dec 15 15:02:48 GMT 2023
FDA ORPHAN DRUG 327910
Created by admin on Fri Dec 15 15:02:48 GMT 2023 , Edited by admin on Fri Dec 15 15:02:48 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 6.3
Created by admin on Fri Dec 15 15:02:48 GMT 2023 , Edited by admin on Fri Dec 15 15:02:48 GMT 2023
Code System Code Type Description
DAILYMED
D83282DT06
Created by admin on Fri Dec 15 15:02:48 GMT 2023 , Edited by admin on Fri Dec 15 15:02:48 GMT 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
FLUCYTOSINE
Created by admin on Fri Dec 15 15:02:48 GMT 2023 , Edited by admin on Fri Dec 15 15:02:48 GMT 2023
PRIMARY Description: A white or almost white, crystalline powder; odourless or almost odourless. Solubility: Sparingly soluble in water; slightly soluble in ethanol (~750 g/l) TS; practically insoluble in ether R. Category: Antifungal drug. Storage: Flucytosine should be kept in a tightly closed container, protected from light.Additional information: Flucytosine melts at about 295 ?C. Definition: Flucytosine contains not less than 98.5% and not more than 101.0% of C4H4FN3O, calculated with reference to the dried substance.
CHEBI
5100
Created by admin on Fri Dec 15 15:02:48 GMT 2023 , Edited by admin on Fri Dec 15 15:02:48 GMT 2023
PRIMARY
NSC
103805
Created by admin on Fri Dec 15 15:02:48 GMT 2023 , Edited by admin on Fri Dec 15 15:02:48 GMT 2023
PRIMARY
RS_ITEM_NUM
1272000
Created by admin on Fri Dec 15 15:02:48 GMT 2023 , Edited by admin on Fri Dec 15 15:02:48 GMT 2023
PRIMARY
SMS_ID
100000091594
Created by admin on Fri Dec 15 15:02:48 GMT 2023 , Edited by admin on Fri Dec 15 15:02:48 GMT 2023
PRIMARY
DRUG BANK
DB01099
Created by admin on Fri Dec 15 15:02:48 GMT 2023 , Edited by admin on Fri Dec 15 15:02:48 GMT 2023
PRIMARY
FDA UNII
D83282DT06
Created by admin on Fri Dec 15 15:02:48 GMT 2023 , Edited by admin on Fri Dec 15 15:02:48 GMT 2023
PRIMARY
NCI_THESAURUS
C501
Created by admin on Fri Dec 15 15:02:48 GMT 2023 , Edited by admin on Fri Dec 15 15:02:48 GMT 2023
PRIMARY
PUBCHEM
3366
Created by admin on Fri Dec 15 15:02:48 GMT 2023 , Edited by admin on Fri Dec 15 15:02:48 GMT 2023
PRIMARY
WIKIPEDIA
FLUCYTOSINE
Created by admin on Fri Dec 15 15:02:48 GMT 2023 , Edited by admin on Fri Dec 15 15:02:48 GMT 2023
PRIMARY
ChEMBL
CHEMBL1463
Created by admin on Fri Dec 15 15:02:48 GMT 2023 , Edited by admin on Fri Dec 15 15:02:48 GMT 2023
PRIMARY
CAS
2022-85-7
Created by admin on Fri Dec 15 15:02:48 GMT 2023 , Edited by admin on Fri Dec 15 15:02:48 GMT 2023
PRIMARY
DRUG CENTRAL
1188
Created by admin on Fri Dec 15 15:02:48 GMT 2023 , Edited by admin on Fri Dec 15 15:02:48 GMT 2023
PRIMARY
ECHA (EC/EINECS)
217-968-7
Created by admin on Fri Dec 15 15:02:48 GMT 2023 , Edited by admin on Fri Dec 15 15:02:48 GMT 2023
PRIMARY
EPA CompTox
DTXSID3023059
Created by admin on Fri Dec 15 15:02:48 GMT 2023 , Edited by admin on Fri Dec 15 15:02:48 GMT 2023
PRIMARY
MERCK INDEX
m5426
Created by admin on Fri Dec 15 15:02:48 GMT 2023 , Edited by admin on Fri Dec 15 15:02:48 GMT 2023
PRIMARY Merck Index
INN
2729
Created by admin on Fri Dec 15 15:02:48 GMT 2023 , Edited by admin on Fri Dec 15 15:02:48 GMT 2023
PRIMARY
HSDB
3082
Created by admin on Fri Dec 15 15:02:48 GMT 2023 , Edited by admin on Fri Dec 15 15:02:48 GMT 2023
PRIMARY
EVMPD
SUB07676MIG
Created by admin on Fri Dec 15 15:02:48 GMT 2023 , Edited by admin on Fri Dec 15 15:02:48 GMT 2023
PRIMARY
MESH
D005437
Created by admin on Fri Dec 15 15:02:48 GMT 2023 , Edited by admin on Fri Dec 15 15:02:48 GMT 2023
PRIMARY
RXCUI
4451
Created by admin on Fri Dec 15 15:02:48 GMT 2023 , Edited by admin on Fri Dec 15 15:02:48 GMT 2023
PRIMARY RxNorm
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
BINDER->LIGAND
BINDING
Related Record Type Details
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 0.6
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC